Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tripegfilgrastim for Prevention of Neutropenia in Pancreaticobiliary Cancer
NCT06135896Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of pegteograstim in neutropenia, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jan 2024; status: recruiting.
02
Drugs
pegteograstim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT06135896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135896.